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Several reports have shown that less aggressive patterns of diagnostic activity and care are
provided to elderly breast carcinoma patients. We sought to investigate whether differences in
the management of older women with breast cancer are associated with survival.
Methods and Findings
In an observational study using a population-based clinical breast cancer register of one
health-care region in Sweden, we identified 9,059 women aged 50–84 y diagnosed with
primary breast cancer between 1992 and 2002. The 5-y relative survival ratio was estimated for
patients classified by age group, diagnostic activity, tumor characteristics, and treatment. The
5-y relative survival for breast cancer patients was lower (up to 13%) in women 70–84 y of age
compared to women aged 50–69 y, and the difference was most pronounced in stage IIB–III
and in the unstaged. Significant differences in disease management were found, as older
women had larger tumors, had fewer nodes examined, and did not receive treatment by
radiotherapy or by chemotherapy as often as the younger women. Adjustment for diagnostic
activity, tumor characteristics, and treatment diminished the relative excess mortality in stages
III and in the unstaged, whereas the excess mortality was only marginally affected in stage IIB.
Conclusions
Less diagnostic activity, less aggressive treatment, and later diagnosis in older women are
associated with poorer survival. The large differences in treatment of older women are difficult
to explain by co-morbidity alone.
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Age should not be a determinant for quality of care in
breast cancer. In Sweden, as in many other countries, the
population is ageing with a rapidly increasing number of
elderly women diagnosed with breast cancer as a conse-
quence. Today about 30% of all breast cancer patients in
Sweden are 70 y or older at diagnosis [1]. Despite this, there
have not hitherto existed any well-established clinical guide-
lines for the management and treatment of breast cancer in
older women. One major reason is that only a few trials have
included, or have been designed for, women over 70 y [2,3].
Therefore, there are little empirical data to support rational
clinical guidelines, which leads to uncertainty about manage-
ment of elderly and, possibly, contributes to age-biased
treatment decisions. Several reports have shown that less
aggressive patterns of diagnostic activity and care are
provided to elderly breast carcinoma patients [3–5], but it is
not clear what these differences mean for survival.
The aim of our study was to investigate whether the
differences in management and diagnosis of breast cancer in
older women have an effect on the survival. We based our
analysis on a population-based clinical database including




We used a population-based regional breast cancer register
for the Uppsala/O ¨ rebro health-care region. The register was
established in 1992, at the same time as formal written clinical
guidelines were issued for the region with the aim to ensure
that all women with breast cancer had the same opportunity
to receive high-quality care. The region comprises seven
counties in Sweden with a total population of about 1.9
million. The register includes individual information about
vital status, age, and date of diagnosis, detection mode,
tumor-stage, biological tumor characteristics, and primary
surgical and oncological treatment. The register includes
97% of all breast cancer patients diagnosed within the region
as validated against the mandatory reporting to the Swedish
Cancer Registry. The main treatment variables and the
staging information have been validated in the register and
over 95% agreement was found.
Within the Uppsala/O ¨ rebro health-care region, all women
aged 50–69 y are regularly invited to mammography screen-
ing for a low out-of pocket fee. Additional age groups are also
invited to screening in some counties, i.e., the age group 40–
49 y in ﬁve counties, the age group 45–49 y in one county, the
age 70 y in one county, and the age group 70–74 y in three
counties.
Participants
Participants were all women with primary breast cancer
reported to the Uppsala/O ¨ rebro regional breast cancer
register from January 1992 to December 2002 (12,163
women), with follow-up until December 2003. We excluded
2,169 (17.8%) women who were under 50 y of age and 867
(7.1%) who were older than 84 y. We chose women 50–69 y as
a reference group for the elderly, since women 50–69 y were
uniformly offered mammography screening and had well-
deﬁned treatment recommendations [6]. We excluded women
over 84 y, since co-morbidity was deemed to play a dominant
role in the choice of treatment for the oldest. From the 9,127
(100%) women aged 50 to 84 y we excluded 68 (0.8%) women
for whom we had less than 1 mo of follow-up. This left us with
9,059 (99.3%) eligible women. In Sweden, treatment recom-
mendations for women over 70 y have been diffuse and are
often left to the judgment of the treating physician.
Ethics
The data used in the study are based on quality assurance
registers legally required for quality assurance of Swedish
health care. The registers are inspected by the Swedish Data
Inspection Board.
Statistical Methods
We compared the 5-y relative survival for primary breast
cancer patients in different age groups (50–69, 70–74, 75–79,
and80–84y).Therelativesurvivalratio(RSR)istheratioofthe
observed survival in the population of interest to the survival
that would have been expected had the patients experienced
only the age- and period-speciﬁc mortality of the general
population from which they were drawn [7]. The general
population in this study is all females in the Uppsala/O ¨ rebro
health-care region. Relative survival is the survival analog of
excess mortality. To study differences in survival between ages
while adjusting for the confounding factors available in the
dataset, i.e., stage (International Union Against Cancer [UICC]
stages I, II, III–IV, and not deﬁnable due to unknown lymph
nodal involvement [or tumor size]), and calendar period of
diagnosis (1992–1993, 1994–1995, 1996–1997, 1998–1999, and
2000–2002), we modeled excess mortality (relative excess rate
[RER] of death) using Poisson regression [8].
We thereafter stratiﬁed the women according to breast
cancer stage to study whether the differences in survival
between ages were consistent across levels of this variable.
To investigate possible differences in management and
treatment of younger versus older patients, we used the
Fisher’s exact test, which tests the independence between age
(dichotomized into 50–69 y versus 70–84 y) and the diagnostic
and treatment variables. The diagnostic variables were pro-
liferation status (high, low, and unknown/missing), estrogen
receptor status (positive, negative, or unknown), number of
lymph nodes examined (1–9, 10þ, no axillary dissection, or
unknown), lymph nodal involvement (positive, negative, or
unknown), and tumor size ( 20 mm, 21–50,  51, or unknown).
The proliferation is measured by s-phase and Ki67, or if data
on these are missing, by Elston grade. We also examined
treatment,classiﬁed asprimary surgical treatment(mastectomy,
breast-conserving, none, or unknown), oncological treatment
(radiotherapy, chemotherapy, or hormonal [tamoxifen]), and
type of treating clinic (main hospital in the county or local
hospital). For women with advanced disease, we also examined
whether they had received any neoadjuvant treatment.
We also constructed a low treatment activity index for
women diagnosed with stage I–III breast cancer and for
whom stage was not deﬁnable. The low treatment activity
index was constructed from the evidence-based clinical
practice guidelines for breast cancer [6]. Since we had no
possibility to control for eventual co-morbidity, general
health, or the women’s own preferences, we used the same
low treatment activity index on all women. Low treatment
activity for women with stage I–II breast cancer was deﬁned
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Breast Cancer Survival in Older Womenas (1) no surgery at all, (2) breast conserving (BCS) without
adjuvant treatment by radiation, (3) no establishment of
estrogen receptor status (except for women with negative
lymph node involvement [N0] and tumor size ,10 mm), (4) no
adjuvant treatment by tamoxifen and/or chemotherapy in
women with positive lymph nodal involvement (N1) and
estrogen receptor–positive breast cancer (ERþ), (5) no
adjuvant treatment by tamoxifen and/or chemotherapy in
women with tumor size more than 20 mm and ERþ, or (6) no
adjuvant treatment by chemotherapy patients with N1 and
estrogen receptor–negative breast cancer (ER ). For women
with a locally advanced disease, low treatment activity was
deﬁned as if (7) they had not received any neoadjuvant
treatment by chemotherapy, hormones, or radiation. For
women whose breast cancer stage is not deﬁnable (due to
missing information on lymph nodal involvement or on
tumor size), points 1–3 explained above were used as an
indication of low treatment activity. We also made a separate
measure of unjustiﬁed over-treatment when women with ER 
breast cancer had received tamoxifen.
Lastly, we studied differences in survival between the ages
while adjusting for the potential determinants (categorized as
explained above) by modeling the excess mortality (RER)
using Poisson regression [8]. To assess the effect of the
different variables, we made separate models for tumor
characteristics, diagnostic activity, and treatment. We also
sought to determine if there was any interaction between age
and type of treatment on excess mortality within stage IIB,
stage III, and the unstaged.
We used the analysis of variance to explore the variation of
tumor size in different age groups (Table 1).
Results
There were large differences regarding how the breast
cancer was detected, i.e., the older the woman, the lower the
probability that her cancer was detected by mammography
Table 1. Distribution of Year of Diagnosis, Stage, and Detection Mode by Age at Diagnosis
Factor Age at Diagnosis p-Value
a
50–69 y 70–74 y 75–79 y 80–84 y
Number (%) Number (%) Number (%) Number (%)
Number of patients
b 5,788 (63.9) 1,261 (13.9) 1,021 (11.3) 989 (10.9)
Year of diagnosis
1992–1993 679 (11.7) 199 (15.8) 142 (13.9) 119 (12.0)
1994–1995 1,030 (17.8) 247 (19.6) 182 (17.8) 171 (17.3)
1996–1997 1,026 (17.7) 221 (17.5) 192 (18.8) 199 (20.1)
1998–1999 1,201 (20.8) 257 (20.4) 223 (21.8) 217 (21.9)
2000–2002 1,852 (32.0) 337 (26.7) 282 (27.6) 283 (28.6)
Detection mode
Screening 3,379 (58.4) 542 (43.0)
c 72 (7.1) 15 (1.5)
Clinical 2,386 (41.2) 713 (56.5) 946 (92.7) 967 (97.8)
Missing 23 (0.4) 6 (0.5) 3 (0.3) 7 (0.7)
Stage at diagnosis
I 2,584 (44.6) 505 (40.1) 298 (29.2) 187 (18.9)
IIA 1,451 (25.1) 304 (24.1) 283 (27.7) 226 (22.9)
IIB 682 (11.8) 160 (12.7) 193 (18.9) 170 (17.2)
III 239 (4.1) 62 (4.9) 69 (6.8) 70 (7.1)
IV 81 (1.4) 28 (2.2) 24 (2.4) 39 (3.9)
Unstaged
d 751 (13.0) 202 (16.0) 154 (15.1) 297 (30.0)
Mean tumor size in the unstaged, mm
e 12.2 16.4 24.2 24.2 ***
Standard error of mean 0.7 1.6 1.8 1.0
Tumor size
1–20 4,039 (69.8) 792 (62.8) 505 (49.5) 404 (40.9)
21–50 1,326 (22.9) 345 (27.4) 391 (38.3) 439 (44.4)
50þ 142 (2.5) 37 (2.9) 41 (4.0) 32 (3.2)
Locally advanced 198 (3.4) 58 (4.6) 69 (6.8) 80 (8.1)
No information 83 (1.4) 29 (2.3) 15 (1.5) 34 (3.4)
Mean tumor size in all patients, mm
e 19.2 21.1
f 25.1 27.6 ***
Standard error of mean 0.2 0.5 0.6 0.6
Lymph node involvement
Positive (N1) 1,704 (29.4) 359 (28.5) 350 (34.3) 281 (28.4)
Negative (N0) 3,331 (57.6) 692 (54.9) 500 (49.0) 365 (36.9)
Unknown (Nþ) 686 (11.9) 160 (12.7) 135 (13.2) 253 (25.6)
Missing 67 (1.2) 50 (4.0) 36 (3.5) 90 (9.1)
ap-Values from analysis of variance in which tumor size is the dependent variable.
bRow percentage.
cIn the three counties where women aged 70–74 y are invited to screening, 59.4% of the women had their cancer detected by screening compared to only 23.9% in three counties where women aged 70–74 y are not invited, and 41.0% in the
county where women aged 70 y (but not aged 71–74 y) are invited.
dStage not definable due to unknown lymph node involvement (95%) or to missing values on tumor size.
eMissing values of tumor size on 149 (10.6%) of 1,404 women with an indefinable stage.
fIn the three counties where women aged 70–74 y are invited to screening, the mean tumor size was 19.0 mm (standard error [SE]¼0.7), compared to 23.7 mm (SE¼0.9) in three counties where women aged 70–74 y are not invited, and 21.4
mm (SE ¼ 1.1) in the county where women aged 70 y (but not aged 71–74 y) are invited.
*p , 0.05; **p , 0.01; ***p , 0.0001.
DOI: 10.1371/journal.pmed.0030025.t001
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Breast Cancer Survival in Older Womenscreening (Table 1). Older women also showed a more
advanced disease with larger tumors and were also more
often unstaged, mainly due to missing information on lymph
node involvement. The proportion of cancer detected by
screening and the mean tumor size was the same for women
aged 70–74 y who had been invited to screening (in three of
the seven counties) as in women aged 50–69 y (see footnote to
Table 1).
The unadjusted 5-y relative survival for breast cancer was
signiﬁcantly lower (by up to 13 percentage units) among
women aged 75–79, and 80–84 y compared to that for women
aged 50–69 y (Table 2). When we adjusted for year and stage,
the difference decreased somewhat (Table 2), mainly due to
the uneven distribution of stages at diagnosis (see Table 1).
Proportional Differences by Age in Diagnostic Activity and
Treatment
Diagnostic activity and treatment differences were ob-
served between women aged 50–69 y and 70–84 y in all stages.
Differences in stages I–IIB. Whereas no major proportional
difference in proliferation status and estrogen receptor status
werefound between theagesinstages I–IIB,a lower proportion
of the older women had had ten or more nodes examined.
Regarding the treatment characteristics stage by stage, a higher
proportion of the women aged 70–84 y, compared to the
women aged 50–69 y, had received mastectomy. As regards the
type of surgery delivered, radiotherapy was much less used in
the elderly, stage by stage. Chemotherapy was also much less
used in the elderly, in agreement with the treatment programs
that regularly do not recommend chemotherapy over the age
of 69 y. The low treatment activity index created for this study
is also considerably higher in the older age group, looking at all
the stages, although the differences are smaller in stage II.
Tamoxifen was, however, more commonly used on the older
women compared to the younger, and the difference seems to
increase with increasing stage (Table 3). A lower proportion of
those 70 y and older are treated in the referral hospital, stage
by stage.
Differences in stages III–IV and the unstaged. For the
stagesIII–IVandtheunstaged(Table4),therewasanincreased
proportion of unknown proliferation status and estrogen
receptor status in the older age groups. There were also a
decreasing number of examined lymph nodes by age in those
undergoing axillary dissection. Regarding the treatment
characteristics for stages III–IV and the unstaged, the pattern
is essentially the same as for stages I–IIB, with a lower
treatment activity amongst the oldest. Although the low
treatment activity index for stage III and for the unstaged is
quitehighforbothagegroups,itishigherfortheolderwomen.
The older women in stages III–IV also more often did not
receiveanysurgeryatall,and,asinearlierstages,radiotherapy
was much less used in the elderly as was chemotherapy. The
difference in the use of tamoxifen was only present in the
unstaged. A difference, as compared to the earlier stages of
breast cancer, is that the differences by age group in the
proportion of women treated at the main hospital of the
countywerenotaspronouncedinthehigherstages.Duetothe
nature of the disease in the higher stages, omitting surgery is
much more common in stages III and IV than in earlier stages.
However, the choice not to resect the tumor is much more
common in the elderly than in the age group 50–69 y.
Adjusted Analyses
Table 5 shows the result of the statistical models in which
the RER is elevated for the elderly in all models in stages IIB
and higher, since these were the stages in which we found
differences by age group in relative survival (see last lines of
Table 3 and 4). The simpler model, which only adjusts for year
of diagnosis, shows the highest RER for the older, whereas the
other models tend to lower the RER as diagnostic activity,
reﬁned stage deﬁnition (by including number of involved
lymph nodes and tumor size), and, ﬁnally, treatment are taken
into account. In the ﬁnal model, the RER for the older age
group is no longer statistically signiﬁcantly elevated, and any
tangible difference only remains for women in stage IIB, with
an RER of 1.26.
We found three statistically signiﬁcant interactions (of 12
examined) between age and type of treatment and excess
mortality, all within stage III. The RER, comparing women
not receiving any surgery to those receiving surgery, was four
times higher among the younger compared to the older (RER
6.4 versus 1.5, respectively), whereas the RERs comparing
excess mortality among women who received radiation versus
no radiation, and chemotherapy versus no chemotherapy
Table 2. Cumulative 5-y RSR of Female Breast Cancer Patients Aged 50–84 y, Diagnosed between 1992 and 2002 (9,059 Women), and
the Estimated RER and 95% Confidence Intervals
Parameter Total Number 5-y Survival Crude
a Adjusted
b
Expected Observed RSR 95% CI RER 95% CI RER 95% CI
Age
50–69 y 5,788 95.9 86.4 90.1 89.1–91.1 1.00 (ref) 1.00 (ref)
70–74 y 1,261 87.0 77.7 89.3 86.4–92.0 1.12 0.84–1.49 1.21 0.97–1.52
75–79 y 1,021 78.8 63.9 81.0 76.8–84.9 2.13 1.68–2.72 1.65 1.36–2.05
80–84 y 989 64.4 49.6 77.0 71.7–82.2 2.89 2.26–3.70 1.72 1.35–2.15
Deviance
c 27 603
Residual df 12 512
aLikelihood ratio test of the effect of age in the model; degrees of freedom (df) ¼ 3, chi-square ¼ 61.11, p , 0.0001.
bModel adjusted for year of (1992–1993, 1994–1995, 1996–1997, 1998–1999, or 2000–2002) and stage (I, IIA, IIB, III, IV, or not definable). Likelihood ratio test of the effect of age in the model; df ¼ 3, chi-square ¼ 31.34, p , 0.0001.
cThe deviance is a measure of the model’s goodness of fit. Under the hypothesis that the model fits, the deviance should follow a chi-square distribution with the specified degrees of freedom.
CI, confidence interval; ref, reference value.
DOI: 10.1371/journal.pmed.0030025.t002
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women (RER 0.3 and 0.4 for younger women compared to 0.9
and 1.3, respectively, among the older) (data not shown).
Discussion
We found large and clinically relevant absolute survival
differences disfavoring women aged 70–84 y as compared to
women aged 50–69 y. Due to the Swedish mammography
screening policies, the stage distribution was more unfavor-
able among the older, but an adjustment for stage could only
partly explain the survival differences. Looking at relative
survival stage by stage, the prognosis was worse in stage IIB
and higher among women over 70 y as compared to those 50–
69 y. Consistently over the stages we found less diagnostic
activity, less use of breast conservation, considerably less use
of chemotherapy, higher ‘‘low activity index,’’ and more often
treatment in local hospitals in older women. Adjusting for
these factors in models largely explained the differences by
age group, except for women in stage IIB. Our large
population-based register lends further strong support to
previous reports [4,9,10] that there is an age bias in manage-
ment of older women.
We used a population-based database with high coverage
and little misclassiﬁcation of the variables used in this
analysis. Another strength is that relative survival provides a
measure of the excess mortality experienced by breast cancer
patients, irrespective of whether excess mortality is directly
or indirectly attributable to cancer [8]. Therefore, we could
study the excess mortality adjusting for the expected survival
in the background population and thereby largely compen-
sate our comparisons for mortality due to co-morbidity.
However, a drawback of the study is the lack of information
on co-morbidity. Co-morbidity may have provided rational
reasons for withholding diagnostic measures or speciﬁc
treatments. One recent study has, however, found non-
rational differences in treatment among older women even
after controlling for co-morbidity [11]. It would also have
been interesting to know whether socioeconomic status is a
determinant for survival, but in essence this would not have
justiﬁed an eventual age bias in management.
An important explanation for the poorer survival among
the elderly was the unfavorable stage distribution due to
considerably less mammography screening activity after 70 y
and no screening taking place after 74 y. This explanation
points to an important health policy issue as the population
Table 3. Proportions and p-Values of Tumor Characteristics and Treatment by Age and Stage I–II at Diagnosis, and the Cumulative 5-y
RSR, RER, and 95% CI
Characteristic and Treatment Stage I p- Value
a Stage IIA p- Value
a Stage IIB p- Value
a
50–69 y 70–84 y 50–69 y 70–84 y 50–69 y 70–84 y
Number (%) Number (%) Number (%) Number (%) Number (%) Number (%)
Proliferation status
High 775 (30.0) 279 (28.2) NS 607 (41.8) 295 (36.3) * 353 (51.8) 231 (44.2) *
Low 1,151 (44.5) 425 (42.9) 568 (39.2) 336 (41.3) 205 (30.1) 182 (34.8)
Unknown 658 (25.5) 286 (28.9) 276 (19.0) 182 (22.4) 124 (18.2) 110 (21.0)
Estrogen status
Positive (ERþ) 1,665 (64.4) 616 (62.2) ** 955 (65.8) 521 (64.1) ** 405 (59.4) 341 (65.2) **
Negative (ER ) 355 (13.7) 110 (11.1) 305 (21.0) 144 (17.7) 182 (26.7) 96 (18.4)
Unknown 564 (21.8) 264 (26.7) 191 (13.2) 148 (18.2) 95 (13.9) 86 (16.4)
No of examined lymph nodes
10þ 1,304 (50.5) 438 (44.2) ** 816 (56.2) 399 (49.1) *** 420 (61.6) 286 (54.7) ***
1–9 1,256 (48.6) 540 (54.6) 627 (43.2) 399 (49.1) 262 (38.4) 224 (42.8)
Unknown 24 (0.9) 12 (1.2) 8 (0.6) 15 (1.9) 0 (0.0) 13 (2.5)
Surgery
Mastectomy 469 (18.2) 323 (32.6) *** 532 (36.7) 498 (61.3) *** 408 (59.8) 412 (78.8) ***
BCS 2,097 (81.2) 656 (66.3) 912 (62.9) 291 (35.8) 268 (39.3) 99 (18.9)
None 1 (0.0) 5 (0.5) 0 (0.0) 15 (1.9) 1 (0.2) 9 (1.7)
Unknown 17 (0.7) 6 (0.6) 7 (0.5) 9 (1.1) 5 (0.7) 3 (0.6)
Radiotherapy 2,023 (78.3) 425 (42.9) *** 1,210 (83.4) 361 (44.4) *** 618 (90.6) 309 (59.1) ***
BCS þ radiotherapy 1,910 (91.1) 389 (59.3) *** 870 (95.4) 217 (74.6) *** 252 (94.0) 80 (80.1) ***
Chemotherapy 123 (4.8) 5 (0.5) *** 566 (39.0) 36 (4.4) *** 403 (59.1) 34 (6.5) ***
Tamoxifen 535 (20.7) 249 (25.2) ** 938 (64.7) 567 (69.7) * 423 (62.0) 411 (78.6) ***
Low treatment activity
b 440 (17.0) 399 (40.3) *** 372 (25.6) 311 (38.3) *** 164 (24.1) 200 (38.2) ***
Tamoxifen and ER  13 (3.7) 5 (4.6) NS 62 (20.3) 40 (27.8) NS 41 (22.5) 37 (38.5) **
Treating clinic main hospital 1,868 (72.3) 646 (65.3) *** 1,046 (72.1) 506 (62.2) *** 482 (70.7) 329 (62.9) ***
RER 1.00 0.08 1.00 0.51 1.00 1.43
5-y RSR 98.9 101.6 91.1 96.0 74.2 64.3
95% CI 0.00–‘ 0.21–1.23 1.09–1.88
ap-Values from a Fishers exact test, testing the independence of the age groups 50–69 y and 70–84 y and diagnostic activity, tumor characteristics, and treatment.
bLow treatment activity for women with stage I–II breast cancer was defined as (1) no surgery at all, (2) BCS without adjuvant treatment by radiation, (3) no establishment of estrogen receptor status (except for women with N0 and tumor size
,10 mm), (4) no adjuvant treatment by tamoxifen and/or chemotherapy in women with N1 and ERþ, (5) no adjuvant treatment by tamoxifen and/or chemotherapy in women with tumor size .20 mm and ERþ, (6) no adjuvant treatment by
chemotherapy patients with N1 and ER . For women with a locally advanced disease, low treatment activity was defined as (7) no neoadjuvant treatment by chemotherapy, hormones, or radiation. For women whose breast cancer is
unstaged, points 1–3 were used as an indication of low treatment activity.
NS, not significant.
* ¼ p , 0.05, ** ¼ p , 0.01, *** ¼ p , 0.0001.
DOI: 10.1371/journal.pmed.0030025.t003
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a life expectancy of 12–16 y.
In stages IIB and higher, radiotherapy was less often used in
older women, and this could not be explained only by the less
frequent use of breast conservation in the elderly. Radio-
therapy in itself, although very effective in reducing relapses
also among elderly [2,12] and generally well tolerated in
higher age groups [13], will not have a major impact on
mortality. However, the use of radiotherapy upon adequate
indications may, in register data, be a proxy variable of the
use of multidisciplinary management and compliance to
clinical recommendations.
Only a very small proportion of the older women received
chemotherapy. This is a consequence of the fact that the
guidelines during this time period often have suggested upper
age limits of 65–70 y for recommending chemotherapy. The
evidence base for effectiveness of chemotherapy in the elderly
is considered weaker than for younger women and only a few
studies of the effect of chemotherapy have included women
over 70 y [2]. A few studies have shown both that older women
( 65 y) have a higher treatment-related mortality than do
younger women [14,15], and that older women in reasonably
good health derive similar beneﬁts (in relation to disease-free
survival and overall survival) from more chemotherapy as the
younger patients [14]. We only found an effect of modiﬁcation
of treatment in stage III, and not in stage IIB and unstaged,
strengthening these ﬁndings. Moreover, co-morbidity has
been found not to be an adequate explanation for why
clinicians decide to use chemotherapy [4], and age alone seems
to be an important indicator of the likelihood to receive
adjuvant chemotherapy [5]. The survival differences by age
group found in our study and studies by others point also to
the importance of further investigating effective adjuvant
systemic treatments in the elderly.
Tamoxifen was widely used in older women in our study.
O n ep o s s i b l er e a s o nf o rt h ed i f f e r e n c ei nu s e( t ot h e
disadvantage of the younger patients) is that during the ﬁrst
half of the 1990s, tamoxifen was considered to have a
negligible effect in younger patients and was therefore not
given to those who received chemotherapy. However, we also
found that with higher age, an increasing proportion of
women with receptor-negative tumors were treated inap-
Table 4. Proportions and p-Values of Tumor Characteristics and Treatment by Age and Stage III–IV and the Indefinable Stage, and the
Cumulative 5-y RSR, RER, and 95% CI
Characteristic and Treatment Stage III p- Value
a Stage IV p- Value
a Unstaged p- Value
a
50–69 y 70–84 y 50–69 y 70–84 y 50–69 y 70–84 y
Number (%) Number (%) Number (%) Number (%) Number (%) Number (%)
Proliferation status
High 115 (48.1) 87 (43.3) NS 28 (34.6) 20 (22.0) * 209 (27.8) 159 (24.4) ***
Low 72 (30.1) 52 (25.9) 19 (23.5) 13 (14.3) 367 (48.9) 218 (33.4)
Unknown 52 (21.8) 62 (30.9) 34 (42.0) 58 (63.7) 175 (23.3) 276 (42.3)
Estrogen status
Positive (ERþ) 153 (64.0) 106 (52.7) ** 37 (45.7) 23 (39.6) NS 494 (65.8) 357 (54.7) ***
Negative (ER ) 56 (23.4) 47 (23.4) 15 (18.5) 14 (15.4) 69 (9.2) 55 (8.4)
Unknown 30 (12.6) 48 (23.9) 29 (35.8) 41 (45.1) 188 (25.0) 241 (36.9)
No of examined lymph nodes
10þ 129 (54.0) 70 (34.8) *** 23 (28.4) 11 (12.1) * 29 (3.9) 11 (1.7) ***
1–9 83 (34.7) 73 (36.3) 14 (17.3) 15 (16.5) 17 (2.3) 14 (2.1)
No axillary dissection 8 (3.4) 19 (9.5) 5 (18.5) 19 (20.9) 655 (85.9) 492 (75.3)
Unknown 19 (8.0) 39 (19.4) 29 (35.8) 46 (50.6) 60 (8.0) 136 (20.8)
Neoadjuvant treatment 112 (46.9) 56 (27.9) *** 22 (27.2) 11 (12.1) *
Surgery
Mastectomy 191 (79.9) 136 (67.7) *** 29 (35.8) 30 (33.0) ** 98 (13.1) 213 (32.6) ***
BCS 31 (13.0) 19 (9.5) 19 (23.5) 5 (5.5) 589 (78.4) 304 (46.6)
None 16 (6.7) 44 (21.9) 33 (40.7) 55 (60.4) 47 (6.3) 128 (19.6)
Unknown 1 (0.4) 2 (1.0) 0 (0.0) 1 (1.1) 17 (2.3) 8 (1.2)
Radiotherapy 177 (74.1) 83 (41.3) *** 24 (29.6) 13 (14.3) * 501 (66.7) 125 (19.1) ***
BCS þ radiotherapy 28 (90.3) 11 (57.9) ** 8 (42.1) 2 (40.0) NS 458 (77.8) 101 (33.2) ***
Chemotherapy 147 (61.5) 32 (15.9) *** 35 (43.2) 5 (5.5) *** 25 (3.3) 2 (0.3) ***
Tamoxifen 120 (50.2) 104 (51.7) NS 27 (33.3) 35 (38.5) NS 92 (12.3) 255 (38.1) ***
Low treatment activity
b 127 (53.1) 145 (72.1) *** — — — 303 (40.4) 404 (61.9) ***
Tamoxifen and ER  7 (12.5) 11 (23.4) NS 2 (13.3) 5 (35.7) NS 4 (5.8) 16 (29.1) ***
Treating clinic main hospital 181 (75.7) 139 (69.2) NS 55 (67.9) 57 (62.6) NS 595 (79.2) 399 (61.1) ***
5-y RSR 61.0 47.5 19.3 17.1 88.6 72.2
RER 1.00 1.47 1.00 1.43 1.00 2.82
95% CI 1.04–2.08 1.00–2.05 2.01–3.96
ap-Values from a Fisher’s exact test, testing the independence of the age groups 50–69 y and 70–84 y and diagnostic activity, tumor characteristics, and treatment.
bLow treatment activity for women with stage I–II breast cancer was defined as (1) no surgery at all, (2) BCS without adjuvant treatment by radiation, (3) no establishment of estrogen receptor status (except for women with N0 and tumor size
,10 mm), (4) no adjuvant treatment by tamoxifen and/or chemotherapy in women with N1 and ERþ, (5) no adjuvant treatment by tamoxifen and/or chemotherapy in women with tumor size .20 mm and ERþ, (6) no adjuvant treatment by
chemotherapy patients with N1 and ER . For women with a locally advanced disease, low treatment activity was defined as (7) no neoadjuvant treatment by chemotherapy, hormones, or radiation. For women whose breast cancer is
unstaged, points 1–3 were used as an indication of low treatment activity.
NS, not significant.
* ¼ p , 0.05, ** ¼ p , 0.01, *** ¼ p , 0.0001.
DOI: 10.1371/journal.pmed.0030025.t004
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ﬁnding is that clinicians felt that some treatment activity is
warranted in women perceived to have a moderate or high
risk of recurrence, but that, in the absence of guidelines
regarding chemotherapy, the clinician took the chance that
tamoxifen would provide some beneﬁt but little harm.
In summary, elderly women were disfavored in several
ways: less use of mammography screening, lower diagnostic
activity, and lower treatment activity, leading to a lower
relative survival. This is a very distressing ﬁnding, since
around 30% of all breast cancer patients are above the age of
70 y. There is an acute need for more empirical evidence
about the effectiveness and tolerability of different treat-
ments in elderly women. Likewise, it is probable that better
structured guidelines for elderly women would be a means to
improve the situation.
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Table 5. Estimated 5-y RER and 95% CI for Women in Different Age Groups, Adjusted for Year of Diagnosis, Diagnostic Activity, Tumor
Characteristics, and Treatments
Model Measure Age Stage IIB Stage III Unstaged
a
RER 95% CI RER 95% CI RER 95% CI
Model 1 50–69 y 1.00 (ref) 1.00 (ref) 1.00 (ref)
70–84 y 1.43 1.09–1.87 1.60 1.13–2.26 1.83 1.27–2.63
Deviance
b 32 34 43
Residual df 38 38 38
Model 2 50–69 y 1.00 (ref) 1.00 (ref) 1.00 (ref)
70–84y 1.38 1.05–1.82 1.32 0.90–1.92 1.20 0.83–1.74
Deviance
b 78 215 287
Residual df 89 264 255
Model 3 50–69 y 1.00 (ref) 1.00 (ref) 1.00 (ref)
70–84 y 1.49 1.12–1.97 1.13 0.76–1.68 1.80 1.27–2.56
Deviance
b 554 416 338
Residual df 635 482 350
Model 4 50–69 y 1.00 (ref) 1.00 (ref) 1.00 (ref)
70–84 y 1.44 1.03–2.02 1.06 0.67–1.68 1.11 0.77–1.61
Deviance
b 462 451 444
Residual df 526 481 504
Model 5 50–69 y 1.00 (ref) 1.00 (ref) 1.00 (ref)
70–84 y 1.26 0.89–1.80 0.91 0.56–1.48 1.07 0.73–1.56
Deviance
b 520 636 807
Residual df 688 859 1108
Model 1: Adjusted for year of diagnosis (1992–1993, 1994–1995, 1996–1997, 1998–1999, or 2000–2002).
Model 2: Adjusted for year of diagnosis and lymph node involvement and tumor size.
Model 3: Adjusted for year of diagnosis and proliferation status, estrogen status, and number of examined lymph nodes. In the modeling for the not-definable stage the variable, number of examined lymph nodes was excluded.
Model 4: Adjusted for year of diagnosis and treatment (surgery, radiotherapy, chemotherapy, or hormonal treatment). In the modeling for stage III, neoadjuvant treatment was also adjusted for.
Model 5: Adjusted for year of diagnosis, lymph node involvement, tumor size, and treatment (surgery, radiotherapy, chemotherapy, or hormonal treatment). In the modeling for stage III, neoadjuvant treatment was also adjusted for.
aStage not definable due to unknown if lymph node involvement (95%) or to missing values on tumor size.
bThe deviance is a measure of the model’s goodness of fit. Under the hypothesis that the model fits, the deviance should follow a chi-square distribution with the specified degrees of freedom (df).
Ref, reference value.
DOI: 10.1371/journal.pmed.0030025.t005
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Background. Breast cancer is the most common cancer in women in
much of the developed world; for example, there are 41,000 new cases in
the UK per year. In 2003, 6,869 women were diagnosed with breast
cancer in Sweden. Survival has improved greatly; in the past ten years in
the UK, the risk of dying of the disease has fallen by one-fifth. The disease
is rare in women under 30 years, but the risk of breast cancer increases
with age. Although there are a number of treatments for breast cancer,
previous work has suggested that certain factors may affect whether a
woman gets treatment. For example, older women are less likely than
younger women to be entered into trials of treatment for breast cancer,
and therefore treatment guidelines are not as clear for older women.
They may also be less likely to receive breast cancer screening.
Why Was This Study Done? The researchers wanted to look at whether
the age of women affected both their survival rate and the treatment
they were likely to receive for breast cancer.
What Did the Researchers Do and Find? They studied 9,059 women
aged 50–84 years, diagnosed with primary breast cancer between 1992
and 2002 in one health-care region in Sweden. The researchers found
that relative survival over five years of women between 70 and 84 years
of age was up to 13% lower compared to women aged 50–69 years. The
difference in survival was most pronounced in women who had been
shown to have more advanced disease or in whom no assessment of the
stage of the disease had been made. There were significant differences
in disease management found; older women had larger tumors, had
fewer lymph nodes examined, and did not receive treatment by
radiotherapy or chemotherapy as often as the younger women.
What Do These Findings Mean? In older women, the diagnosis of
breast cancer was often made later than in younger women. Once
diagnosed, older women were less likely to be fully investigated for their
cancer, and had less aggressive treatment. It is possible that other
illnesses (co-morbidities) in these women may have meant that they
were less likely to survive the cancer, but this cannot be the main cause
of the differences, and diagnosis in older women is associated with
poorer survival. The large differences in treatment of older women are
difficult to explain by co-morbidity alone. Even in a country such as
Sweden with good health care, age results in great differences in the
diagnosis and care of women with breast cancer, with older women
faring much worse than younger women.
Where Can I Get More Information Online? The US National Cancer
Registry has a page with many links to information on breast cancer,
including prevention and treatment:
http://www.cancer.gov/cancertopics/types/breast
Cancer Research UK, a large UK charity that funds research into breast
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